Protalix BioTherapeutics (PLX) Assets Average (2011 - 2026)

Protalix BioTherapeutics' Assets Average history runs 15 years deep, the most recent figure standing at $92.3 million for Q1 2026.

• On a quarterly basis, Assets Average rose 25.37% year-over-year to $92.3 million in Q1 2026; TTM through Mar 2026 was $92.3 million, a 25.37% increase from a year earlier, with the FY2025 full-year figure at $77.9 million, down 1.32% from the prior year.
• Assets Average improved to $92.3 million in Q1 2026 per PLX's latest filing, from $82.3 million in the prior quarter.
• Across five years, Assets Average topped out at $92.3 million in Q1 2026 and bottomed at $56.2 million in Q4 2022.
• The 5-year median for Assets Average is $76.6 million (2024), against an average of $75.9 million.
• Across the five-year window, Assets Average slumped 38.85% in 2022 and jumped 52.9% in 2023, its largest moves.
• Year by year, Assets Average stood at $56.2 million in 2022, then soared by 52.9% to $86.0 million in 2023, then dropped by 21.52% to $67.5 million in 2024, then advanced by 21.95% to $82.3 million in 2025, then gained by 12.19% to $92.3 million in 2026.
• Per Business Quant, the three latest PLX Assets Average figures stand at $92.3 million (Q1 2026), $82.3 million (Q4 2025), and $80.4 million (Q3 2025).